Research programme: cancer therapeutics - CorMedix/NanoProteagen

Drug Profile

Research programme: cancer therapeutics - CorMedix/NanoProteagen

Alternative Names: CRMD 005/vincristine; CRMD-005; Taurolidine/vincristine - CorMedix; Vincristine/taurolidine - CorMedix

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CorMedix; National Cancer Institute (USA)
  • Developer CorMedix
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Cell adhesion molecule inhibitors; Deoxyribonuclease 1 stimulants; Lipopolysaccharide inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Neuroblastoma

Most Recent Events

  • 26 Feb 2018 Preclinical trials in Cancer (In children, In infants) in USA (unspecified route)
  • 26 Feb 2018 Preclinical trials in Neuroblastoma (In children, In infants) in USA (unspecified route)
  • 22 Feb 2018 Taurolidine receives Orphan Drug status for Neuroblastoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top